Taken together, KChIP3 (calsenilin) with its target proteins PS1 and PS2 plays a critical role in both APP γ-cleavage and ER Ca2+ release, functions which are dysregulated in Alzheimer’s disease [53]. This evidence concerns the gene APP and early-onset autosomal dominant Alzheimer disease.